Beyond Single Targets: How Bispecific ADCs Are Redefining Precision Oncology

The ADC Revolution Gets a Dual Upgrade

Antibody-drug conjugates have long been celebrated as one of oncology’s most elegant ideas: attach a potent cytotoxic agent to a tumor-targeting antibody, deliver the payload precisely where it’s needed, and spare the surrounding healthy tissue. For years, that formula worked remarkably well — until the inevitable limitations emerged. Antigen heterogeneity, target downregulation, and acquired resistance have challenged even the most optimized single-target agents. Enter the next chapter: bispecific antibody-drug conjugates (BsADCs).

By engineering a single molecule capable of engaging two different antigens simultaneously, BsADC technology is addressing the shortcomings of its predecessors head-on. In 2025, the momentum behind this approach has become impossible to ignore. More than 100 bispecific ADC candidates are now advancing through preclinical and early investigational pipelines globally, and a wave of high-quality research publications is fleshing out exactly how, and why, this strategy works.

This post digs into the science behind five of the most compelling target axes currently under exploration — BCMA, CD22, PSMA, CD79B, and TGFβ — and explains why preclinical research in these areas is accelerating so rapidly right now.

Why “Bispecific” Changes Everything

Traditional ADCs rely on a single antibody arm binding one surface antigen. This works well when the target is uniformly overexpressed — but tumors are notoriously heterogeneous. Subpopulations of cancer cells within the same tumor mass often express different antigen profiles, and some may downregulate the primary target entirely after initial treatment, leading to relapse.

Bispecific ADCs tackle this on multiple fronts. First, by requiring two simultaneous binding events for full activation, they can dramatically increase tumor selectivity: normal tissues rarely co-express the same combination of antigens as tumor cells. Second, the dual-engagement mechanism typically enhances receptor-mediated internalization — a critical step for payload delivery — because crosslinking two surface proteins together accelerates endocytosis. Third, the “AND-gate” logic of dual targeting significantly reduces the probability that a tumor cell will successfully evade treatment through antigen escape alone.

A 2024 review published in Acta Pharmaceutica Sinica B encapsulated this succinctly, framing BsADCs as a “1+1>2” strategy — not because the math is literal, but because the synergistic effects routinely exceed what either targeting arm could achieve alone. That insight is now driving a focused surge of preclinical work across five high-priority target classes.

Five High-Priority Targets Driving BsADC Research

Not all target combinations are created equal. Successful BsADC design requires careful consideration of target co-expression patterns, internalization kinetics, antigen density, and the immunological context of the tumor microenvironment. Here are five axes where the preclinical science is particularly rich right now.

Closer Look: The Science Behind Each Target

BCMA — The Myeloma Mainstay Gets a Bispecific Boost

B-cell maturation antigen (BCMA) remains the cornerstone of advanced multiple myeloma therapy. While several approved therapies already exploit this target, resistance and relapse remain clinical realities. Researchers are now exploring BCMA-based bispecific ADCs that pair cytotoxic payload delivery with simultaneous engagement of a second myeloma-associated antigen. Preclinical data from 2024–2025 show that co-targeting BCMA alongside antigens such as CD38 can overcome resistance mechanisms associated with BCMA downregulation, and the AND-gate internalization mechanism enhances payload delivery efficiency compared to monospecific controls. A key area of current research involves optimizing the antibody format — particularly the hinge geometry between the two binding domains — to maximize simultaneous dual engagement without steric clash.

CD22 — Fast Internalization Meets Dual Targeting in B-Cell Malignancies

CD22’s unusually rapid receptor internalization rate, with near-complete recycling within 30–60 minutes of antibody binding, has long made it a favorite backbone for ADC design. What makes CD22-based bispecific ADCs particularly exciting in 2025 is the ability to combine this efficient delivery vehicle with a second arm targeting CD19, CD20, or CD79B, creating a molecule that addresses both rapid payload internalization and the problem of antigen heterogeneity in relapsed B-cell lymphomas. Recent preclinical studies have demonstrated that dual CD22/CD19 BsADCs can eliminate antigen-low tumor subpopulations that partially escape single-target therapy, translating to deeper and more durable tumor control in mouse xenograft models.

PSMA — Expanding the Reach of ADCs into Solid Tumors

Prostate-specific membrane antigen (PSMA) is one of the most validated targets in urologic oncology, with high and consistent overexpression in castration-resistant prostate cancer and minimal expression on most normal tissues. However, tumor heterogeneity and stromal barriers have limited the efficacy of monospecific PSMA-targeted agents. The emerging generation of PSMA-based bispecific ADCs is designed to overcome these barriers by adding a second arm that can recognize TROP2 or STEAP1, two antigens frequently co-expressed in advanced prostate lesions. This combination not only improves tumor cell avidity but also allows the bystander killing effect of membrane-permeable payloads to eliminate neighboring PSMA-low cells. Some research groups are additionally investigating PSMA × CD3 BsADC formats that combine direct payload delivery with T-cell redirecting activity, creating a dual cytotoxic-immunological mechanism.

CD79B — From Single Agent to Synergistic Partner in Lymphoma

CD79B’s story is one of rapid scientific evolution. As a validated ADC target — established through extensive preclinical and clinical work — CD79B now serves as a springboard for more sophisticated bispecific designs. CD79B-based bispecific ADCs under preclinical investigation typically pair this B-cell receptor component with CD20 or CD22, exploiting the co-expression pattern that is nearly universal in mature B-cell malignancies. A 2025 study characterizing anti-CD79B/CD3 bispecific constructs noted that the B-cell receptor complex engagement triggered by CD79B binding also activates downstream signaling that synergizes with payload-induced apoptosis — a mechanism not observed with CD79B monospecific ADCs. This unexpected pharmacological synergy has reinvigorated interest in CD79B as a key node in bispecific designs for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

TGFβ — Turning the Immunosuppressive Microenvironment Against Itself

Perhaps no target on this list represents a more paradigm-shifting concept than TGFβ. Transforming growth factor beta is not a tumor cell surface antigen in the traditional sense; it is a pleiotropic cytokine that tumors co-opt to suppress anti-tumor immune responses, promote cancer-associated fibroblast activity, and drive epithelial-to-mesenchymal transition. TGFβ-based bispecific ADCs typically combine a tumor antigen–targeting arm (such as anti-HER2, anti-EGFR, or anti-FAP) with an arm that sequesters or neutralizes TGFβ in the tumor microenvironment. The resulting molecule simultaneously delivers cytotoxic payload to tumor cells while dismantling the immunosuppressive barrier that prevents endogenous T cells from recognizing and eliminating residual disease. Early preclinical data from 2024–2025 suggest this “attack-and-immunize” strategy can convert immunologically “cold” tumors into “hot” ones — a transformation that has profound implications for combination with checkpoint inhibitors in future research settings.

The 2025 Preclinical Research Landscape: Key Themes

Across all five target axes, several overarching themes are shaping the current generation of BsADC research in the preclinical space:

Format diversity is accelerating. Researchers are moving well beyond the classic full-length IgG scaffold. Current preclinical candidates include asymmetric IgG-like formats (knobs-into-holes, CrossMAb), bispecific nanobody fusions, IgM-based constructs for enhanced avidity, and compact single-chain formats optimized for tissue penetration in solid tumors. Each format brings distinct pharmacokinetic profiles, and selecting the right architecture for a given target combination is now recognized as a critical design variable.

Linker and payload science is maturing. The payload landscape has expanded dramatically beyond auristatin and maytansinoid derivatives. Topoisomerase I inhibitors, pyrrolobenzodiazepine dimers, and novel RNA-polymerase inhibitors are being explored as BsADC payloads, with each offering different bystander killing profiles, resistance mechanisms, and tolerability windows. Cleavable linker chemistry is also advancing rapidly, with pH-sensitive, protease-responsive, and glutathione-cleavable designs offering increasingly precise control over release kinetics.

Computational and AI-assisted design is entering the room. Several research groups published in 2025 on the application of machine learning models to predict optimal arm-to-arm geometry, linker attachment site selection, and drug-to-antibody ratio (DAR) configurations for bispecific scaffolds. These computational tools are beginning to shorten the empirical design cycle and reduce the number of conjugate variants that need to be synthesized and tested.

Resistance mechanism mapping is a growing priority. As first-generation ADCs have moved through clinical development, the field has gained hard-won insight into resistance pathways — including target antigen loss, lysosomal dysfunction, and efflux pump upregulation. Preclinical BsADC programs in 2025 are increasingly designed from the start to preempt these mechanisms, incorporating second arms specifically chosen to remain expressed under the same selection pressures that downregulate the primary target.

Building the Evidence Base: Preclinical Studies That Matter

Rigorous preclinical characterization is the foundation upon which the entire BsADC field is built. For any of these target combinations to advance responsibly, researchers need a comprehensive toolkit spanning molecular biology, biochemistry, cell-based assays, and animal model pharmacology.

On the molecular side, establishing binding affinity and selectivity for both target antigens is the first critical checkpoint. Surface plasmon resonance, biolayer interferometry, and flow cytometry-based binding assays are standard approaches, but for bispecific constructs, simultaneous dual-binding assays are essential to confirm that both arms function correctly without interfering with each other. The conformational geometry of dual engagement — whether binding one antigen alters the affinity or orientation of the second arm — must be empirically tested, not assumed.

In cell-based studies, target co-expression patterns on tumor cell lines and primary patient samples should be carefully characterized before investing in full conjugate synthesis. Internalization kinetics following bispecific engagement (versus monospecific controls) need to be measured, and the intracellular trafficking route — whether the construct reaches lysosomes efficiently — must be confirmed, as this directly determines payload release efficiency.

At the in vivo level, syngeneic and humanized mouse models each play distinct roles. Syngeneic systems are valuable for examining interactions with the immune microenvironment — particularly relevant for TGFβ-targeting designs — while patient-derived xenograft (PDX) models provide the closest approximation to clinical antigen heterogeneity. Pharmacokinetic/pharmacodynamic (PK/PD) profiling, tumor accumulation studies using fluorescent or radiolabeled constructs, and safety assessments in antigen-expressing normal tissues all contribute to the evidence package needed to differentiate a preclinical BsADC candidate.

Looking Ahead: What the Next 12–18 Months May Bring

The trajectory of bispecific ADC research in 2025 points toward several exciting near-term developments. In the hematologic oncology space, expect to see increasingly sophisticated BCMA and CD22/CD79B combination designs that directly address the resistance patterns now well-characterized from first-generation programs. In solid tumors, the PSMA field is likely to generate compelling preclinical data packages in the next 12 months as improved humanized prostate cancer models become more widely available.

The TGFβ-incorporating designs represent perhaps the most conceptually interesting frontier: if early in vivo models confirm the “immune cold to hot” conversion hypothesis, this class could become a compelling preclinical basis for entirely new combination strategies. It is one of the few approaches that attempts to address both direct tumor cell killing and the immunological context simultaneously within a single molecule.

Broadly, the field is moving toward greater modularity — the idea that bispecific ADC design can be approached as a rational assembly of validated components (an internalization arm, a co-targeting arm, a linker system, a payload class) rather than a de novo empirical exercise. As the component libraries expand and the design rules become better understood through accumulated preclinical data, the pace of BsADC development is expected to accelerate further.

For researchers and organizations working at the preclinical interface — generating the molecular constructs, characterization data, and in vivo evidence packages that form the scientific foundation of this field — the BsADC space in 2025 represents one of the richest and most technically rewarding areas in all of oncology research.

This article is intended for scientific and educational purposes only. All product and service references relate to preclinical research use. Creative Biolabs does not provide clinical-stage development services.

Created in March 2026